MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference

Merck, Bristol Myers Squibb, Biogen and others presented their latest data from multiple sclerosis (MS) programs at the 38th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Amsterdam.

Some data highlighted a mostly positive overlap with treatment regimens for other diseases such as COVID-19.